CoChat

Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy

Open access
Makuku, Rangarirai, Khalili, Neda, Razi, Sepideh, Keshavarz-Fathi, Mahsa, Rezaei, Nima · 2021 · Journal of Immunology Research

The DOI matches its Crossref record; 169 of the 169 references it cites were found in a registry or an index.

Abstract

Cancer immunotherapy, which reactivates weakened immune cells of cancer patients, has yielded great success in recent years. Among immunotherapeutic agents, immune checkpoint inhibitors have been of particular interest and have gained approval by the FDA for treatment of cancers. Immune checkpoint blockade through targeting programmed cell death protein-1 (PD-1) has demonstrated promising antitumor effects in cancer immunotherapy of many different solid and hematologic malignancies. However, despite promising results, a favorable response is observed only in a fraction of patients, and there is still lack of a single therapy modality with curative ability. In this paper, we review the current and future perspectives of PD-1/L1 blockade in cancer immunotherapy, with a particular focus on predictive biomarkers of response to therapy. We also discuss the adverse events associated with PD-1/L1/2 inhibitors, ranging from severe life-threatening conditions such as autoimmune myocarditis to mild and moderate reactions such as skin rashes, and explore the potential strategies for improving the efficacy of immunotherapy with PD-1/L1 checkpoint inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2021/6661406

Cites

169 of 169 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Mechanism of action of PD-1/L1 checkpoint blockade. PD-1: programmed cell death protein-1; TCR: T cell receptor; PDL-1/2: programmed death-ligand 1/2; APC: antigen presenting cell; MHC1: major histocompatibility complex 1; CTLA4: cytotoxic T-lymphocyte-associated protein 4.
Figure 1 Mechanism of action of PD-1/L1 checkpoint blockade. PD-1: programmed cell death protein-1; TCR: T cell receptor; PDL-1/2: programmed death-ligand 1/2; APC: antigen presenting cell; MHC1: major histocompatibility complex 1; CTLA4: cytotoxic T-lymphocyte-associated protein 4.CC BY · PubMed Central
Figure 2 The regulatory effects of PD-1 inhibition on downstream signaling pathways. TCR: T cell receptor; PD-1: programmed cell death protein-1; ZAP70: zeta-chain-associated protein kinase 70; AP1: activator protein 1; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; NFAT: nuclear factor of activated T cells; PLCγ: phosphoinositide phospholipase C-γ; LCK: lymphocyte-specific protein-tyrosine kinase; mAbs: monoclonal antibodies; CTL: cytotoxic T-lymphocyte.
Figure 2 The regulatory effects of PD-1 inhibition on downstream signaling pathways. TCR: T cell receptor; PD-1: programmed cell death protein-1; ZAP70: zeta-chain-associated protein kinase 70; AP1: activator protein 1; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; NFAT: nuclear factor of activated T cells; PLCγ: phosphoinositide phospholipase C-γ; LCK: lymphocyte-specific protein-tyrosine kinase; mAbs: monoclonal antibodies; CTL: cytotoxic T-lymphocyte.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Z. R. Kelly, 2019, The Financial and Physical Toxicity of Immune Checkpoint Inhibitors in Cancer Alexandria

Cited by

See all 136

Metadata

Authors
Makuku, R., Khalili, N., Razi, S., Keshavarz-Fathi, M., & Rezaei, N.
Affiliations
  • Universal Scientific Education and Research Network (IR)
  • Iran University of Medical Sciences (IR)
  • Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran
Corresponding author
Rezaei, Nima
Venue
Journal of Immunology Research
Publisher
Wiley
Published
2021-02-22
Volume
2021
Pages
1-15
ISSN
  • 2314-7156 (ISSN-L)
  • 2314-8861
OpenAlex
W3129917327
Cited by
136
References
169
Citations by year
2026: 15 · 2025: 19 · 2024: 33 · 2023: 29 · 2022: 29 · 2021: 11
FWCI
3.09
Type
journal article
Language
en
Open access
Locations
  • Journal of Immunology Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
PD-1/PD-L1 blockade, immune checkpoint inhibitors, cancer immunotherapy, predictive biomarkers, immune-related adverse events, autoimmune myocarditis, immunotherapy efficacy, hematologic malignancies, solid tumors
MeSH terms
Antineoplastic Agents, Immunological, Immune Checkpoint Inhibitors, Immune Checkpoint Proteins, Animals, Humans, Immunotherapy, Neoplasms, Biomarkers, Tumor, Signal Transduction, Treatment Outcome, Molecular Targeted Therapy, B7-H1 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.